VivoSeq
Other

Primary

0

Pipeline Programs↗

4

Active Trials↗

1

Companies Involved↗

Primary is an early-stage landscape with 0 programs across 1 company. The most active players are Daiichi Sankyo.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

15/100

Mech. Concentration

N/A

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Daiichi Sankyo logo

Daiichi Sankyo

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

4

clinical trials

Recruiting2 · 50%
Not yet recruiting2 · 50%

Clinical Trials

Trial Activity

Prospective Reduction Of Transplant Complications Through Enhanced Preservation Therapy to Prevent Primary Graft Dysfunction
Recruiting·UUniversity Health Network, Toronto·Preclinical·NCT07230886·50 enrolled
Exercise Intervention in Primary Antibody Deficiency Disorders: A 12-week Feasibility Study
Not yet recruiting·YYale University·Preclinical·NCT07698197·20 enrolled
Effectiveness and Safety of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia: an Observational Study
Recruiting·Daiichi Sankyo logoDaiichi Sankyo·N/A·NCT06686615·2,000 enrolled
Comparison of the Effects of Needle Biopsy Tract Resection and Non-resection on Recurrence Rate in Patients With Primary Extremity Sarcoma: Study Protocol of a Randomized, Non-inferior Clinical Trial
Not yet recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT07575724·3,300 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)